DALLAS, Nov. 19, 2025 /PRNewswire/ -- Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, today announced that patient dosing is underway in a ...

JSKN003 has shown a 63% objective response rate and 7.7 months median progression-free survival in PROC patients, with higher efficacy in HER2-positive subgroups. The FDA's fast track designation ...

Therapeutic advances across the gynecologic cancer continuum have resulted in improvements in patient care and outcomes over the past decade, yet challenges remain. In ovarian cancer, the evolution of ...

"The interim results demonstrated a highly differentiated clinical profile for TUB-040 in the ADC field, with anti-tumor activity beginning at low doses with a broad therapeutic window that could ...

The Trump administration's unusual step to make the U.S. government one of the largest shareholders in a major Silicon Valley company raises important questions about how that partnership will ...

A new SQL Server 2025 feature lets organizations run vector-based semantic searches on their own data, connecting to local or cloud-hosted AI models without relying on massive general-purpose LLMs. I ...

Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Organizations are using generative AI to stay ahead of the competition, but the real advantage lies in harnessing the power of your own data securely and at scale. One of the most exciting new ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...